What is Soligenix Inc Annual Net Profit?

Soligenix Inc Annual Net Profit fell 34.62% in the last year to $8.27 M. Its sector's average net profit growth for the last fiscal year was -32.26%.

What is Soligenix Inc Price to Earning Ratio?

Soligenix Inc Price to Earning Ratio is -0.7, which is negative.

What is Soligenix Inc Stock Price?

Soligenix Inc Stock Price fell 75.53% and underperformed its sector by 74.81% in the past year.

What is Soligenix Inc Quarterly Net profit?

Soligenix Inc Quarterly Net profit fell 64.15% YoY to $2.99 M. Its sector's average net profit growth YoY for the quarter was -47.42%.

What is Soligenix Inc Debt to Equity Ratio?

Soligenix Inc Debt to Equity Ratio of 0.36 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

What is Soligenix Inc Return on Equity(ROE)?

Soligenix Inc Return on Equity(ROE) for the last financial year was -248.97%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

What is Soligenix Inc Mutual Fund Holding?

Soligenix Inc Mutual Fund Holding decreased by 0.24% in the last quarter to 1.39.

What is Soligenix Inc Promoter Share Holding?

Soligenix Inc Promoter Share Holding stayed the same in the most recent quarter at 1.38%.

What is Soligenix Inc Institutional Holding?

Soligenix Inc Institutional Holding remained the same in the last quarter at 0.97%.

How is the Soligenix Inc today?

The Soligenix Inc today is trading in the down by -11.54% at 1.84.

How has Soligenix Inc performed historically?

The Soligenix Inc is currently trading down -11.54% on an intraday basis in the past week the index fell -16.74%. The index has been down -41.21% in the past quarter and fell -75.53% in the past year. You can view this in the overview section.

Soligenix Inc XNAS: SNGX

Soligenix Inc Live Share Price Today, Share Analysis and Chart

Name: Soligenix Inc: Is Infosys Ltd. worth buying?
Item: Soligenix Inc
Rating: 0.82683325
Author: Trendlyne DVM scores

Download real time

1.84 -0.24 (-11.54%)

New 52W Low today

52,914 XNAS Volume

XNAS 04 Apr, 2025 5:30 PM (EDT)

Soligenix Inc Key Metrics

My Metrics

Select

Market Capitalization Low in industry Unavailable in chosen country	5.8
PE TTM Negative PE TTM Unavailable in chosen country	-0.7
Price to Book Below industry Median Unavailable in chosen country	1.4
Institutional holding current Qtr % Low in industry Unavailable in chosen country	1
Operating Revenue growth TTM % Negative Operating Revenue growth TTM % Unavailable in chosen country	-54.5
Net Profit Qtr Growth YoY % Negative Net Profit Qtr Growth YoY % Unavailable in chosen country	-64.2
Net Profit TTM Growth % Negative Net Profit TTM Growth % Unavailable in chosen country	-34.6
Operating Profit Margin TTM % Negative Operating Profit Margin TTM % Unavailable in chosen country	-7,987.7
Piotroski Score Low in industry Unavailable in chosen country	1
Rel Perf vs Sector quarter% Unavailable in chosen country	-38
ROE Annual % Negative ROE Annual % Unavailable in chosen country	-249
RoA Annual % Negative RoA Annual % Unavailable in chosen country	-88.1

All financials are in USD Million and price data in USD

Not Eligible

Expensive Valuation

10.8 / 100

Technically Bearish

22.2 / 100

1Yr Price target upside is 1802%

1 analysts

Check Before You Buy

Check P/E Buy Sell Zone

This stock has negative PE

Soligenix Inc Stock Price Analysis

Day Price Range -11.5% 1 Day return Unavailable in chosen country	1.8 (LTP) 1.72.1 LowHigh
Week Price Range -16.7% 1 Week return Unavailable in chosen country	1.8 (LTP) 1.72.3 LowHigh
Month Price Range -16.4% 1 Month return Unavailable in chosen country	1.8 (LTP) 1.72.4 LowHigh
52 Week Price Range -75.5% 1 Year return Unavailable in chosen country	1.8 (LTP) 1.785.3 LowHigh

View full Share Price History

Soligenix Inc Live Price Chart

Switch to TradingView

Fetching data ...

Forecaster - Analyst Share Price Target and Estimates

Hit

Soligenix Inc's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

QUARTER
ANNUAL

Current EPS

-7

Avg. Estimate

-7

Low Estimate

-7

High Estimate

-7

Current EPS

Avg. Estimate

Forecaster is a Premium Feature

You need to upgrade your subscription plan to access this feature

Upgrade Now

Soligenix Inc Stock Analysis

Soligenix Inc stock analysis with key metrics, changes, and trends.

Soligenix Inc Metric	VALUE	CHANGE %	TREND	ANALYSIS
Annual Net Profit	$8.27 M	34.62%	negative	Annual Net Profit fell 34.62% in the last year to $8.27 M. Its sector's average net profit growth for the last fiscal year was -32.26%.
Price to Earning Ratio	-0.7	-	negative	Price to Earning Ratio is -0.7, which is negative.
Stock Price	$1.84	-75.53%	negative	Stock Price fell 75.53% and underperformed its sector by 74.81% in the past year.
Quarterly Net profit	$2.99 M	64.15%	negative	Quarterly Net profit fell 64.15% YoY to $2.99 M. Its sector's average net profit growth YoY for the quarter was -47.42%.
Debt to Equity Ratio	0.36	-	positive	Debt to Equity Ratio of 0.36 is less than 1 and healthy. This implies that its assets are financed mainly through equity.
Return on Equity(ROE)	-248.97 %	-248.97%	negative	Return on Equity(ROE) for the last financial year was -248.97%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.
Mutual Fund Holding	1.39 %	-0.24%	negative	Mutual Fund Holding decreased by 0.24% in the last quarter to 1.39.
Promoter Share Holding	1.38 %	0%	neutral	Promoter Share Holding stayed the same in the most recent quarter at 1.38%.
Institutional Holding	0.97 %	0%	neutral	Institutional Holding remained the same in the last quarter at 0.97%.

VIEW LESS

Loading data..

Soligenix Inc - Company Profile

What does Soligenix Inc do?

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

2024

Gross Remuneration

Year

Soligenix Inc Live Share Price Today, Share Analysis and Chart

New 52W Low today

Soligenix Inc Key Metrics

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

Market Capitalization

PE TTM

Price to Book

Institutional holding current Qtr %

Operating Revenue growth TTM %

Net Profit Qtr Growth YoY %

Net Profit TTM Growth %

Operating Profit Margin TTM %

Piotroski Score

Rel Perf vs Sector quarter%

ROE Annual %

RoA Annual %

SWOT Analysis

Check Before You Buy

Check P/E Buy Sell Zone

Soligenix Inc Stock Price Analysis

Day Price Range

Week Price Range

Month Price Range

52 Week Price Range

Soligenix Inc Live Price Chart

Forecaster - Analyst Share Price Target and Estimates

Revenue forecast

Soligenix Inc's Revenue was higher than average estimate 2 times in past 3 years

EPS forecast

Soligenix Inc Stock Analysis

Soligenix Inc stock analysis with key metrics, changes, and trends.

Annual Net Profit fell 34.62% in the last year to $8.27 M. Its sector's average net profit growth for the last fiscal year was -32.26%.

Price to Earning Ratio is -0.7, which is negative.

Stock Price fell 75.53% and underperformed its sector by 74.81% in the past year.

Quarterly Net profit fell 64.15% YoY to $2.99 M. Its sector's average net profit growth YoY for the quarter was -47.42%.

Debt to Equity Ratio of 0.36 is less than 1 and healthy. This implies that its assets are financed mainly through equity.

Return on Equity(ROE) for the last financial year was -248.97%, less than 10%, indicating an inefficient use of shareholder's capital to generate profit.

Mutual Fund Holding decreased by 0.24% in the last quarter to 1.39.

Promoter Share Holding stayed the same in the most recent quarter at 1.38%.

Institutional Holding remained the same in the last quarter at 0.97%.

Soligenix Inc - Company Profile

What does Soligenix Inc do?

Soligenix Inc Management structure

Dr. Christopher J. Schaber,PhD

Chairman of the Board, Chief Executive Officer and President

Dr. Oreola Donini, PhD

Chief Scientific Officer and Senior Vice President

Mr. Jonathan L. Guarino, C.P.A.

Chief Financial Officer, Principal Accounting Officer, Senior Vice President and Corporate Secretary

Dr. Richard Straube, M.D.

Senior Vice President and Chief Medical Officer

Soligenix Inc Board of directors

Dr. Robert J. Rubin,M.D.

Independent Director

Mr. Gregg Anthony Lapointe, C.P.A.,M.B.A.

Independent Director

Dr. Jerome Bernard Zeldis, M.D.,PhD

Independent Director

Ms. Diane L. Parks, M.B.A.

Independent Director

Dr. Christopher J. Schaber,PhD

Chairman of the Board, Chief Executive Officer and

Soligenix Inc FAQ

How is Soligenix Inc today?

Soligenix Inc today is trading in the red, and is down by -11.54% at 1.84.

How has Soligenix Inc performed historically?

Soligenix Inc is currently trading down -11.54% on an intraday basis. In the past week the stock fell -16.74%. stock has been down -41.21% in the past quarter and fell -75.53% in the past year. You can view this in the overview section.